17 0 1



MacroGenics has a portfolio of proprietary cancer stem-like cells from many types of primary tumors. These cancer stem cells are maintained in vitro, and small numbers of these cells can form both localized and metastatic tumors in vivo. MacroGenics has more than 2,000 monoclonal antibodies (representing more than 75 targets) derived from its proprietary technology platform. Many of these mAbs target cancer stem cells and cancers of the lung, colon, pancreas, prostate, breast and ovary. 

MacroGenics is pursuing development of the most promising targets it has identified to create new therapeutic candidates. Such candidates are being evaluated in combination with the company’s Fc Optimization and DART technology platforms.  Learn more about MacroGenics’ Antibody Technology Platforms
MacroGenics is developing several mAb-based therapeutics targeting infectious disease pathogens.
Smallpox mAb
Smallpox is caused by the variola virus and is a contagious and sometimes fatal infectious disease. Following a significant public health campaign, naturally occurring smallpox was eradicated in 1977; however, smallpox is now considered a biothreat agent. Through funding by NIH, MacroGenics is developing an antibody cocktail based on its DART technology for post-exposure prophylaxis.
H5N1 mAb
H5N1 is an avian disease. There is some evidence of limited human-to-human transmission of the virus. A risk factor for contracting the virus is handling of infected poultry, but transmission of the virus from infected birds to humans is inefficient. Still, around 60% of humans known to have been infected with the current Asian strain of H5N1 have died from it, and H5N1 may mutate or reassort into a strain capable of efficient human-to-human transmission. Due to the high lethality and virulence of H5N1, its endemic presence, its increasingly large host reservoir, and its significant ongoing mutations, the H5N1 virus is the world's largest current pandemic threat. Through funding by NIH, MacroGenics is developing an antibody for post-exposure prophylaxis.
Dengue mAb
Dengue fever and dengue hemorrhagic fever are acute febrile diseases, found in the tropics and Africa, and caused by four closely related virus serotypes of the genus Flavivirus. The geographical spread is similar to that of malaria, including northern Australia, Singapore, Malaysia, Taiwan, Thailand, Vietnam, Indonesia, Philippines, Pakistan, India, Bangladesh, Puerto Rico, Brazil, Guyana, Venezuela, Trinidad and Samoa. Unlike malaria, dengue is just as prevalent in the urban districts of its range as in rural areas. Each serotype is sufficiently different that there is no cross-protection and epidemics caused by multiple serotypes (hyperendemicity) can occur. Dengue is transmitted to humans by the Aedes aegypti or more rarely the Aedes albopictus mosquito, which feed during the day. Through funding by NIH, MacroGenics is developing an antibody for post-exposure prophylaxis.

mAbs Directed Against Other Viral Pathogens
In 2010, MacroGenics was awarded two NIH grants related to infectious disease pathogens.  These grants, both of which fall under NIH’s “Partnerships for Biodefense Viral Pathogens,” cover research and development activities to create an antibody-based therapy for Chikungunya Virus and a DART-based pan-Dengue Virus immunotherapeutic for prophylaxis and treatment of Dengue Virus. Both viruses are insect-borne and transmitted to humans by virus-carrying mosquitoes. Dr. Michael Diamond at Washington University in St. Louis developed the Chikungunya and Dengue antibodies and is the grantee for the Chikungunya Virus award; MacroGenics is the sub-recipient.
MacroGenics is seeking strategic partners to participate in the development of its various product candidates and technology platforms. Learn more